Medline Announces Public Filing of Registration Statement with the SEC

Medline (MDLN) filed a registration statement on Form S-1 with the SEC on October 28, 2025 for a proposed initial public offering of common stock.

Rhea-AI Summary

Medline (MDLN) filed a registration statement on Form S-1 with the SEC on October 28, 2025 for a proposed initial public offering of common stock. The offering is subject to market and other conditions and the registration statement must become effective before any sale.

The number of shares, price range and final terms have not been determined. If completed, Medline intends to list on the Nasdaq Global Select Market under the symbol MDLN. Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan are lead bookrunning managers.

Positive

• Form S-1 publicly filed on October 28, 2025
• Intends to list on Nasdaq Global Select Market under MDLN
• Major lead bookrunners named: Goldman Sachs, Morgan Stanley, BofA, J.P. Morgan

Negative

• Number of shares and price range not yet determined
• Offering subject to SEC effectiveness and market conditions

Insights

Capital markets analyst

Medline filed a Form S-1 for a proposed IPO; terms are undetermined and effectiveness is required before any sale.

Medline publicly filed a registration statement on Form S-1 on Oct 28, 2025 seeking a proposed initial public offering and intends to list under MDLN on the Nasdaq Global Select Market. The filing names Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan as lead bookrunners. The company discloses that the number of shares, price range and other terms remain undetermined and that the offering is subject to market and other conditions.

The announcement creates a clear near-term dependency on the SEC registration becoming effective and on market conditions; no proceeds, valuation, or dilution metrics are provided. Watch for the preliminary prospectus filing and the effectiveness decision, plus any disclosed share count and price range, which will materially change the financial implications and timing for market participation in the weeks to months following this Oct 28, 2025 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORTHFIELD, Ill., Oct. 28, 2025 /PRNewswire/ -- Medline Inc. announced today that it has publicly filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its common stock. The offering is subject to market and other conditions, including effectiveness of such registration statement, and there can be no assurance as to whether or when the offering may be commenced or completed. The number of shares to be offered and the price range and other terms for the offering have not yet been determined.

If the offering is completed, Medline Inc. intends to list its stock on the Nasdaq Global Select Market under the symbol "MDLN."

Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as lead bookrunning managers for the proposed offering.

The proposed offering will be made only by means of a prospectus. Once available, a copy of the preliminary prospectus relating to the proposed offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001  or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

A registration statement on Form S-1 related to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Media Contacts:
Karen King
Global Head Investor Relations
+1.847.247.7222
Karen.King@medline.com

Ben Fox
Vice President
Corporate Communications
+1.224.327.9999
BeFox@medline.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medline-announces-public-filing-of-registration-statement-with-the-sec-302597214.html

SOURCE Medline Industries, LP

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When did Medline file its S-1 for the proposed IPO (MDLN)?

Medline filed a registration statement on Form S-1 with the SEC on October 28, 2025.

Will Medline list on an exchange and what will the ticker be if the IPO completes?

If the offering is completed, Medline intends to list on the Nasdaq Global Select Market under the ticker MDLN.

Have Medline's IPO share count and price range been set for MDLN?

No; the number of shares and the price range have not yet been determined.

Who are the lead bookrunning managers for Medline's proposed MDLN offering?

Lead bookrunners are Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan.

Can investors buy Medline shares before the S-1 becomes effective?

No; the securities may not be sold and offers to buy may not be accepted prior to SEC effectiveness.

Where can I obtain a copy of Medline's preliminary prospectus for the MDLN IPO?

A preliminary prospectus will be available from the listed lead managers' prospectus departments once released.